#AIM IMMUNO TECH UPDATE#
#AIM IMMUNO TECH FULL#
#AIM IMMUNO TECH TRIAL#

#AIM IMMUNO TECH UPDATE#

The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.Principal component analysis, or PCA, is a statistical procedure that allows you to summarize the information content in large data tables by means of a smaller set of “summary indices” that can be more easily visualized and analyzed.

#AIM IMMUNO TECH TRIAL#

There is also the potential for delays in clinical trial enrollment and reporting because of the COVID-19 medical emergency. Additionally, studies and trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. No assurances can be given as to whether any studies will be successful or yield favorable data. While the results of the CHDR study indicate the safety and tolerability of repeated intranasal administration of Ampligen, significant additional testing will be required to confirm whether Ampligen is an effective prophylactic or early treatment against COVID-19 or any other respiratory viral infections. The CHDR presentation at the ESWI Conference concerns interim results, and the Company awaits a final study report. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA.

Many of these forward-looking statements involve a number of risks and uncertainties. Words such as “may,” “will,” “expect,” “plan,” “anticipate” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”).

For more information, please visit Cautionary Statement is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

#AIM IMMUNO TECH FULL#

The complete presentation is available on the AIM ImmunoTech website in the events/presentations section.ĪIM expects to receive the full study report from CHDR in January 2022.ĪIM ImmunoTech Inc. The study reported no Severe Adverse Events at any dosage level. A total of 40 healthy subjects received either Ampligen or a placebo in the trial, with the Ampligen given at four escalating dosages across four cohorts, to a maximum level of 1,250 micrograms.

The Centre for Human Drug Research (CHDR) presented previously announced data from a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as a potential intranasal therapy. The conference also included research on COVID-19 and respiratory syncytial virus. (NYSE American: AIM) today announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific Working Group on Influenza (ESWI) virtual conference in Salzburg, Austria, on December 4-7, 2021. 09, 2021 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc.

Aim immuno tech